23 completed, 3 unknown, 2 withdrawn, 1 terminated. 29 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 29 | Completed 23, Unknown 3, Withdrawn 2, Terminated 1 |
| Phase 2 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Osteopenia: new trials by email Literature Review of Osteopenia trials Research Report on Osteopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BP Limb Length of 60cm vs 100cm in Roux-en-Y Gastric Bypass biliopancreatic limb length of 60cm., biliopancreatic limb length of 100cm. - Osteopenia | Phase 3 | Unknown | Hospital General Universitario Elche | 200 | 2020-05-07 | 2020-05-06 |
| Denosumab vs Zoledronate After Lumbar Fusion Denosumab 60 mg/ml [Prolia], Zoledronate - Osteopenia, Lumbar Spondylolisthesis | Phase 3 | Unknown | Shenzhen People's Hospital | 100 | 2020-01-15 | 2023-02-21 |
| Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women Oligopin, Placebo - Osteopenia | Phase 3 | Completed | Tehran University of Medical Sciences | 43 | 2018-02-01 | 2020-05-20 |
| Heartland Osteoporosis Prevention Study Calcium Carbonate, Vitamin D3, Risedronate - Osteopenia | Phase 3 | Completed | University of Nebraska | 276 | 2015-02-01 | 2023-10-05 |
| Functional Yogurt Powder Effect on Bone Health Biomarkers Functional yogurt powder, Control yogurt powder - OSTEOPENIA | Phase 3 | Completed | Instituto de Investigación Hospital Universitario La Paz | 79 | 2015-01-01 | 2015-12-14 |
| Effect of Electromyostimulation on Bone wellness control group., whole-body electromyostimulation - Osteopenia, Sarcopenia | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 78 | 2011-01-01 | 2015-12-02 |
| Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D Placebo, Vitamin D3 - Primary Hyperparathyroidism, Hypercalcemia | Phase 2 / Phase 3 | Withdrawn | Columbia University | 2010-05-01 | 2015-03-05 | |
| Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Denosumab, Placebo - Cancer, Cataract | Phase 3 | Completed | Amgen | 769 | 2009-11-30 | 2017-05-30 |
| Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer Risedronate, Placebo - Breast Cancer, Menopause | Phase 3 | Completed | Hospices Civils de Lyon | 20 | 2009-11-01 | 2013-10-31 |
| Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis 60 mg denosumab, Placebo - Low Bone Mass, Low Bone Mineral Density | Phase 3 | Completed | Amgen | 242 | 2009-10-01 | 2018-10-17 |
| Osteoporosis Prevention With Low Dose Alendronate alendronate, Calcium/Vitamin D, placebo - Osteopenia | Phase 3 | Completed | University Hospital of Mont-Godinne | 83 | 2007-09-01 | 2013-05-29 |
| Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis Denosumab - Osteopenia, Osteoporosis | Phase 3 | Completed | Amgen | 4550 | 2007-08-07 | 2022-11-07 |
| A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density denosumab - Low Bone Mineral Density, Osteopenia | Phase 3 | Completed | Amgen | 311 | 2007-05-01 | 2013-10-31 |
| The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause Juvent 1000 Dynamic Motion Therapy (DMT) Platform - Bone Density, Osteopenia | Phase 3 | Completed | University Health Network, Toronto | 202 | 2006-11-01 | 2010-04-08 |
| A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density. Alendronate, Denosumab - Osteoporosis, Osteopenia | Phase 3 | Completed | Amgen | 1189 | 2006-05-01 | 2011-01-24 |
| Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method Placebo comparator, risedronate - Osteopenia | Phase 3 | Completed | Warner Chilcott | 161 | 2006-04-01 | 2012-01-11 |
| Study to Evaluate the Safety and Efficacy of Seasonale for Treatment of Low Bone Mineral Density Seasonale (levonorgestrel and ethinyl estradiol) - Osteopenia | Phase 3 | Withdrawn | Duramed Research | 2005-07-01 | 2013-08-12 | |
| Effect of Exercise Training and Soy-based Nutritional Supplementation on Prevention of Osteoporosis exercise/soy isoflavone - Osteoporosis, Osteopenia | Phase 3 | Completed | University of Saskatchewan | 351 | 2004-12-01 | 2011-09-13 |
| To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women zoledronic acid - Osteopenia | Phase 3 | Completed | Novartis | 455 | 2004-12-01 | 2012-04-27 |
| AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer Placebo, AMG 162 / Denosumab - Breast Cancer, Low Bone Mineral Density | Phase 3 | Completed | Amgen | 252 | 2004-10-01 | 2018-10-17 |
Showing 20 of 29. Sign in to see all of them.
Bone Diseases, Metabolic (29) · Osteoporosis (16) · Breast Neoplasms (2) · Motor Activity (2) · Osteoporosis, Postmenopausal (2) · Amenorrhea (1) · Cataract (1) · Crohn Disease (1) · Fractures, Bone (1) · Hip Fractures (1) · Hypercalcemia (1) · Hyperparathyroidism, Primary (1) · Multiple Endocrine Neoplasia Type 1 (1) · Neoplasms (1) · Pain (1)
Bone Diseases (29) · Metabolic Diseases (29) · Musculoskeletal Diseases (29) · Nutritional and Metabolic Diseases (29) · Neoplasms by Site (4) · Neoplasms (3) · Behavior (2) · Breast Diseases (2) · Endocrine System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Wounds and Injuries (2) · Atrophy (1) · Avitaminosis (1)
Denosumab (7) · Alendronate (4) · Zoledronic Acid (4) · Risedronic Acid (3) · Cholecalciferol (2) · Vitamin D (2) · Calcium (1) · Calcium Carbonate (1) · Drugs, Generic (1) · Estradiol (1) · Estrogens (1) · Ethinyl Estradiol (1) · Genistein (1) · Injections, Subcutaneous (1) · Levonorgestrel (1)
Amgen (6) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (2) · Bayer (1) · Columbia University (1) · Duramed Research (1) · Glaser Pediatric Research Network (1) · Hospices Civils de Lyon (1) · Hospital General Universitario Elche (1) · Instituto de Investigación Hospital Universitario La Paz (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Shenzhen People's Hospital (1) · Tehran University of Medical Sciences (1) · University Health Network, Toronto (1)
United States (10) · Canada (6) · Australia (3) · France (3) · Germany (2) · Russia (2) · South Africa (2) · Argentina (1) · Belgium (1) · Bulgaria (1) · China (1) · Czechia (1) · Greece (1) · Hungary (1) · India (1)
Allison Case, M.D. (1) · Angela M Cheung, M.D., Ph.D. (1) · Carmen Gomez Candela, MD, PhD (1) · Celia Rodd, MD FRCPC (1) · Clifford Rosen, MD (1) · Emily von Scheven, MD (1) · Francesco Squadrito, MD (1) · Gioacchino D'Alo, MD (1) · H J Biem, M.D. (1) · Jaime Ruiz-Tovar (1) · Joan M. Lappe, PhD, RN (1) · Laura Bilek, PT, PhD (1)
PMID 38979716, PMID 17577003, PMID 18767928, PMID 20168099, PMID 21037195, PMID 21824950, PMID 22084333, PMID 22113951, PMID 22152181, PMID 23979955, PMID 27576310, PMID 34519832
2009 (1), N01AR002245 (1), R01AR048932 (1), R01DK084986 (1)